Flavoxate

CHEMBL1493 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.5 g/mol
LogP
4.3
Phase
4

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

Moleküler Ağırlık

391,5000 g/mol

LogP

4,30

TPSA

55,80 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O

InChI

InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

Molecular Formula

C24H25NO4

HBD / HBA

- / 5

Döndürülebilir Bağlar

6

Ağır Atomlar

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Flavoxate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1493. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3354. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.